L-amino acid oxidase isolated from bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 2, 2013, Pages 103-112

  Burin, Sandra M ^a   Ayres, Lorena R ^a   Neves, Renata P ^a   Ambrósio, Luciana ^a   De Morais, Fabiana R ^a   Dias Baruffi, Marcelo ^a   Sampaio, Suely V ^a   Pereira Crott, Luciana S ^a   De Castro, Fabíola A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID OXIDASE; BCR ABL PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CELL MARKER; DACTINOMYCIN; IMATINIB;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOTHROPS; BOTHROPS PIRAJAI; CELL ACTIVATION; CELL STRAIN HL 60; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ISOLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BOTHROPS; CASPASE 3; CASPASE 8; CASPASE 9; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HL-60 CELLS; HUMANS; L-AMINO ACID OXIDASE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

BOTHROPS PIRAJAI;

EID: 84880252256     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12073     Document Type: Article

References (66)

1. Di Bacco A, Keeshan K, Mckenna SL, Cotter TG. Molecular abnormalities in chronic myeloid leukaemia. Deregulation of cell growth and apoptosis. Oncologist 2000;5:405-15.
2. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukaemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-21.
3. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2003;1:132-52.
4. von Landgraeber S, Knoch M, Löer F, Wegner A, Tsokos M, Hussmann B et al. Extrinsic and intrinsic pathways of apoptosis in aseptic loosening after total hip replacement. Biomaterials 2008;29:3444-50.
5. Putcha GV, Harris CA, Moulder KL, Easton RM, Thompson CB, Johnson EM Jr. Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J Cell Biol 2002;157:441-53.
6. Kim NH, Kim K, Park WS, Son HS, Bae Y. J PKB/Akt inhibits ceramide-induced apoptosis in neuroblastoma cells by blocking apoptosis-inducing factor (AIF) translocation. Cell Biochem 2007;5:1160-70.
7. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011;60:1173-80.
8. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998;16:1383-90.
9. Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP. Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. FEBS Lett 2003;541:57-63.
10. Sawyers CL. Chronic myelogenous leukemia. N Engl J Med 1999;340:1330-40.
11. Castro FA, Palma PV, Morais FR, Voltarelli JC. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation. Braz J Med Biol Res 2004;37:201-6.
12. Thienelt CD, Green K, Bowles DW. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today (Barc) 2012;48:601-13.
13. Weisberg E, Griffin J. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003;6:231-8.
14. Mahon F, Deininger MW, Schultheis N, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
15. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
16. Kantarjian H. Sawyers Cl Guilhot F Schiffer C.; Gambacorti-Passerini C Niederwieser D. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
17. Shah NP, Nicoll JM, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
18. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
19. Radich JP. Chronic myeloid leukaemia: where are we now and where can we go? Hematology Am Soc Hematol Educ Program 2010;2010:122-8.
20. Ferdinand R, Mitchell SA, Batson S, Tumur I. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 2012;3:51-76.
21. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012;26:214-24.
22. Vaidya S, Ghosh K, Vundinti BR. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 2011;87:381-93.
23. Izidoro LFM, Ribeiro MC, Souza GR. Sant'ana CD Hamaguchi A Homsi-Brandeburgo MI et al. Biochemical and functional characterization of an L-amino acid oxidase isolated from Bothrops pirajai snake venom. Bioorg Med Chem 2006;14:7034-43.
24. de Vieira Santos MM, Sant'Ana CD, Giglio JR, da Silva RJ, Sampaio SV, Soares AM et al. Antitumour effect of an L-amino acid oxidase isolated from Bothrops jararaca snake venom. Basic Clin Pharmacol Toxicol 2008;102:533-42.
25. Alves RM, Antonucci GA, Paiva HH, Cintra AC, Franco JJ, Mendonça-Franqueiro EP et al. Evidence of caspase-mediated apoptosis induced by L-amino acid oxidase isolated from Bothrops atrox venom. Comp Biochem Physiol part A Mol Integr Physiol 2008;151:542-50.
26. Warrel DA. Snake bite. Lancet 2010;375:77-88.
27. Correa-Netto C, Teixeira-Araujo R, Aguiar AS, Melgarejo AR, De-Simone SG, Soares MR. Immunome and venome of Bothrops jararacussu: a proteomic approach to study the molecular immunology of snake toxins. Toxicon 2010;55:1222-35.
28. Curti B, Ronchi S, Simonetta PM. Flavoenzyme. Chem Biochem 1992;3:69-94.
29. Souza DH, Eugenio LM, Fletcher JE, Jiang MS, Garratt RC, Oliva G et al. Isolation and structural characterization of a cytotoxic L-amino acid oxidase from Agkistrodon contortrix laticinctus snake venom: preliminary crystallographic data. Arch Biochem Biophys 1999;368:285-90.
30. Sakurai Y, Takatsuka H, Yoshioka A, Matsui T, Suzuki M, Titani K et al. Inhibition of human platelet aggregation by L-amino acid oxidase purified from Naja naja kaouthia venom. Toxicon 2001;39:1827-33.
31. Lu QM, Wei Q, Jin Y, Wei JF, Wang WY, Xiong YL. L-amino acid oxidase from Trimeresurus jerdonii snake venom: purification, characterization, platelet aggregation-inducing and antibacterial effects. J Nat Toxins 2002;11:345-52.
32. Sakurai Y., Shima M, Matsumoto T, Takatsuka H, Nishiya K, Kasuda S et al. Anticoagulant activity of M-LAO, L-amino acid oxidase purified from Agkistrodon halys blomhoffii, through selective inhibition of factor IX. Biochim Biophys Acta 2003;1649:51-7.
33. Wei JF, Wei Q, Lu QM, Tai H, Jin Y, Wang WY et al. Purification, characterization and biological activity of an L-amino acid oxidase from Trimeresurus mucrosquamatus venom. Acta Biochem. Biophys Sin 2003;35:219-24.
34. Zhang YJ, Wang JH, Lee WH, Wang Q, Liu H, Zheng YT et al. Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity. Biochem Biophys Res Commun 2003;309:598-604.
35. Stabeli RG, Sant'ana CD, Ribeiro PH, Costa TR, Ticli FK, Pires MG et al. Cytotoxic L-amino acid oxidase from Bothrops moojeni: biochemical and functional characterization. Int J Biol Macromol 2007;41:132-4032.
36. Rodrigues RS, Silva JF, França B, Fonseca FP, Otaviano AR, Henrique-Silva F et al. Structural and functional properties of Bp-LAAO, a new L-amino acid oxidase isolated from Bothrops pauloensis snake venom. Biochemie 2009;91:490-501.
37. Zuliani JP, Kayano AM, Zaqueo KD, Coutinho-Neto A, Sampaio SV, Soares AM et al. Snake venom L-amino acid oxidases: some consideration about their functional characterization. Protein Pept Lett 2009;16:908-12.
38. Sun M, Guo C, Tian Y, Chen D. Biochemical, functional and structural characterization of Akbu-LAAO: a novel snake venom L-amino acid oxidase from Agkistrodon blomhoffii ussurensis. Biochimie 2010;92:343-9.
39. Stiles BG, Sexton FW, Weinstein SA. Antibactericidal effects of different snake venoms: purification and characterization of antibacterial proteins from Pseudechis australis (Australian king brown or mulga snake) venom. Toxicon 1991;29:1129-41.
40. Du XY, Clemetson KJ. Snake venom L-amino acid oxidases. Toxicon 2002;40:659-65.
41. Lee ML, Tan NH, Fung SF, Sekaran D. Antibacterial action of a heat-stable form of L-amino acid oxidase isolated from king cobra (Ophiophagus hannah) venom. Comp Biochem Physiol C Toxicol Pharmacol 2011;153:237-42.
42. Suhr SM, Kim DS. Identification of the snake venom substance that induces apoptosis. Biochem Biophys Res Commun 1996;224:134-9.
43. Wei JF, Yang HW, Wei XL, Qiao LY, Wang WY, He SH. Purification, characterization and biological activities of the L-amino acid oxidase from Bungarus fasciatus snake venom. Toxicon 2009;54:262-71.
44. Strober W. Wright-Giemsa and nonspecific esterase staining of cells. Curr Protoc Cytom. 2001 Appendix 3:Appendix 3D.
45. Pessatti M, Fontana JD, Furtado MF, Guimãraes MF, Zanette LR, Costa WT et al. Screening of Bothrops snake venoms for L-amino acid oxidase activity. Appl Biochem Biotechnol 1995;51-52:197-210.
46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
47. Clement LT, Dagg MK, Lehmeyer JE. Kiyotaki. Two phenotypically distinct suppressor T cell subpopulations inhibit the induction of B cell differentiation by phytohemagglutinin. J Immunol 1983;131:1214-7.
48. Licastro F, Davis LJ, Morini MC. Lectins and superantigens: membrane interactions of these compounds with T-lymphocytes affect immune response. Int J Biochem 1993;25:845-52.
49. Nicoletti L, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
50. Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012;96:1-9.
51. Neto EH, Coelho ALJ, Sampaio ALF, Henriques MGMO, De Marcinkiewicz C, Freitas MS et al. Activation of human T lymphocytes via integrin signaling induced by RGD-disintegrins. Biochim Biophys Acta 2007;2:176-84.
52. + T lymphocytes. Toxicol Appl Pharmacol 2003;193:97-105.
53. Ahn MY, Lee BM, Kim YS. Characterization and cytotoxicity of L-amino acid oxidase from the venom of king cobra (Ophiphagus hannah). Int J Biochem Cell Biol 1997;29:911-9.
54. + CML cells. Biochem Pharmacol 2010;80:1662-75.
55. Hengartner MO. The biochemistry of apoptosis. Nature 2000;12:770-6.
56. Bueno-Da-Silva AEB, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 2003;10:592-8.
57. Skulachev VP. Programmed death phenomena: from organelle to organism. Ann N Y Acad Sci 2002;959:214-37.
58. Sun LK, Yoshii Y, Hyodo A, Tsurushima H, Saito A, Harakuni T et al. Apoptotic effect in the glioma cells induced by specific protein extracted from Okinawa Habu (Trimeresurus flavoviridis) venom in relation to oxidative stress. Toxicol In Vitro 2003;17:169-77.
59. Zhang L, Wu T. Isolation and characterization of ACTX-6: a cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom. Nat Prod Res 2008;22:554-63.
60. Tempone AG, Spencer PJ, Lourenco CO, Rogero JR, Nascimento N. Bothrops moojeni venom kills Leishmania spp. with hydrogen peroxide generated by its L-amino acid oxidase. Biochem Byophys Res Commun 2001;280:620-4.
61. Imlay J. Pathways of oxidative damage. Annu Rev Microbiol 2003;57:395-418.
62. Okubo BM, Silva ON, Migliolo L, Gomes DG, Porto WF, Batista CL et al. Evaluation of an antimicrobial L-amino acid oxidase and peptide derivatives from Bothropoides mattogrosensis pitviper venom. PLoS ONE 2012;7:1-10.
63. Yang CA, Cheng CH, Liu SY, Lo CT, Lee JW, Peng KC. Identification of antibacterial mechanism of L-amino acid oxidase derived from Trichoderma harzianum ETS 323. FEBS J 2011;278:3381-94.
64. Ande SR, Kommoju PR, Draxl S, Murkovic M, Ghisla S, Fröhlich KU et al. Induction of apoptosis in yeast by L-amino acid oxidase from the Malayan pit viper Calloselasma rhodostoma. Yeast 2008;25:349-57.
65. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273-8.
66. Kumar S, Mishra N, Raina D, Saxena S, Kufe D. Abrogation of the cell death response to oxidative stress by the c-abl tyrosine kinase inhibitor STI571. Mol Pharmacol 2002;63:276-82.